JP6951449B2 - (+)−2−ボルネオールの、スフィンゴシンキナーゼ−1および/又はbdnfの発現の上方制御を促進する医薬の調製における使用 - Google Patents
(+)−2−ボルネオールの、スフィンゴシンキナーゼ−1および/又はbdnfの発現の上方制御を促進する医薬の調製における使用 Download PDFInfo
- Publication number
- JP6951449B2 JP6951449B2 JP2019537248A JP2019537248A JP6951449B2 JP 6951449 B2 JP6951449 B2 JP 6951449B2 JP 2019537248 A JP2019537248 A JP 2019537248A JP 2019537248 A JP2019537248 A JP 2019537248A JP 6951449 B2 JP6951449 B2 JP 6951449B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- brain
- sphingosine kinase
- borneol
- upregulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ラット局所脳虚血再灌流モデル
マウス運動皮質限局性虚血モデルにおける(+)−2−ボルネオールの長期的な薬物動態学試験
Claims (6)
- 前記スフィンゴシンキナーゼ−1および/又は脳由来神経栄養因子の発現の上方制御を促進する医薬の作用で、スフィンゴシンキナーゼ−1の発現を2〜4倍上方制御することを特徴とする請求項1に記載の医薬。
- 前記スフィンゴシンキナーゼ−1および/又は脳由来神経栄養因子の発現の上方制御を促進する医薬の作用で、脳由来神経栄養因子の発現を2〜4倍上方制御することを特徴とする請求項1又は2に記載の医薬。
- スフィンゴシンキナーゼ−1および脳由来神経栄養因子の発現を同時に上方制御することを特徴とする請求項1〜3のいずれか1項に記載の医薬。
- 剤形が、カプセル剤、錠剤、粒剤、散剤、注射剤又は滴丸であることを特徴とする請求項1〜4のいずれか1項に記載の医薬。
- 剤形が注射剤であることを特徴とする請求項5に記載の医薬。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/092148 WO2019006734A1 (zh) | 2017-07-07 | 2017-07-07 | (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020504152A JP2020504152A (ja) | 2020-02-06 |
JP6951449B2 true JP6951449B2 (ja) | 2021-10-20 |
Family
ID=64950502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019537248A Active JP6951449B2 (ja) | 2017-07-07 | 2017-07-07 | (+)−2−ボルネオールの、スフィンゴシンキナーゼ−1および/又はbdnfの発現の上方制御を促進する医薬の調製における使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200261375A1 (ja) |
EP (1) | EP3578174A4 (ja) |
JP (1) | JP6951449B2 (ja) |
CN (1) | CN110248649A (ja) |
WO (1) | WO2019006734A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023065071A1 (zh) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | 莰醇在制备治疗缺血性脑卒中的药物中的用途 |
WO2023066162A1 (zh) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | 莰醇在制备治疗缺血性脑卒中的药物中的用途 |
CN116919930A (zh) * | 2022-04-06 | 2023-10-24 | 沈阳药科大学 | 萜类化合物在调节脑膜淋巴循环促进脑内异常蛋白通过淋巴途径清除中的应用 |
CN118045071B (zh) * | 2024-04-15 | 2024-06-07 | 苏州沪云新药研发股份有限公司 | 一种治疗缺血性脑卒中疾病的联合用药物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102180832B (zh) * | 2011-03-18 | 2012-09-12 | 苏州沪云肿瘤研究中心有限公司 | 脑缺血保护用化合物及制备方法 |
CN105012292A (zh) * | 2014-04-17 | 2015-11-04 | 米文君 | 一种药物组合物及其用途 |
CN105232528A (zh) * | 2014-07-10 | 2016-01-13 | 米文君 | 一种药物组合物及其用途 |
CN105879036A (zh) * | 2016-04-14 | 2016-08-24 | 成都大学 | 一种冰片和载药纳米粒的组合物在治疗脑部疾病中的应用 |
-
2017
- 2017-06-07 US US16/488,062 patent/US20200261375A1/en not_active Abandoned
- 2017-07-07 CN CN201780085223.4A patent/CN110248649A/zh active Pending
- 2017-07-07 EP EP17916830.7A patent/EP3578174A4/en not_active Withdrawn
- 2017-07-07 JP JP2019537248A patent/JP6951449B2/ja active Active
- 2017-07-07 WO PCT/CN2017/092148 patent/WO2019006734A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN110248649A (zh) | 2019-09-17 |
EP3578174A1 (en) | 2019-12-11 |
WO2019006734A1 (zh) | 2019-01-10 |
US20200261375A1 (en) | 2020-08-20 |
JP2020504152A (ja) | 2020-02-06 |
EP3578174A4 (en) | 2020-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chmielarz et al. | Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies | |
Peng et al. | Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage | |
Rana et al. | Unfolding the role of BDNF as a biomarker for treatment of depression | |
JP6951449B2 (ja) | (+)−2−ボルネオールの、スフィンゴシンキナーゼ−1および/又はbdnfの発現の上方制御を促進する医薬の調製における使用 | |
Dill et al. | Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS | |
Hanani et al. | Satellite glial cells and astrocytes, a comparative review | |
Kim et al. | Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system | |
Johnson et al. | Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents | |
Mahadik et al. | Gangliosides in treatment of neural injury and disease | |
Li et al. | Rh-IFN-α attenuates neuroinflammation and improves neurological function by inhibiting NF-κB through JAK1-STAT1/TRAF3 pathway in an experimental GMH rat model | |
US20030229134A1 (en) | Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type 4 | |
Di Cesare Mannelli et al. | Antidepressant-like effect of artemin in mice: a mechanism for acetyl-L-carnitine activity on depression | |
Itzekson et al. | Reversal of trauma-induced amnesia in mice by a thrombin receptor antagonist | |
Chen et al. | Blocking GluN2B subunits reverses the enhanced seizure susceptibility after prolonged febrile seizures with a wide therapeutic time-window | |
Zhai et al. | A1 adenosine receptor attenuates intracerebral hemorrhage-induced secondary brain injury in rats by activating the P38-MAPKAP2-Hsp27 pathway | |
Bordet et al. | Mechanism of action of s1p receptor modulators in multiple sclerosis: the double requirement | |
Wang et al. | Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats | |
Liu et al. | Carvedilol promotes retinal ganglion cell survival following optic nerve injury via ASK1-p38 MAPK pathway | |
Chen et al. | Retracted: Allopregnanolone restores the tyrosine hydroxylase‐positive neurons and motor performance in a 6‐OHDA‐injected mouse model | |
Paulzen et al. | Effects of psychotropic drugs on brain plasticity in humans | |
Li et al. | RP001 hydrochloride improves neurological outcome after subarachnoid hemorrhage | |
Du et al. | Synaptic plasticity in the pathophysiology and treatment of bipolar disorder | |
Huang et al. | Na+/K+-ATPase: ion pump, signal transducer, or cytoprotective protein, and novel biological functions | |
Li et al. | P2Y6 Receptor Activation Aggravates NLRP3-dependent Microglial Pyroptosis via Downregulation of the PI3K/AKT Pathway in a Mouse Model of Intracerebral Hemorrhage | |
DUMAN | 32| MOLECULAR AND CELLULAR PATHOGENESIS OF DEPRESSION AND MECHANISMS FOR TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190704 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200908 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210622 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210622 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210630 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210705 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210830 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210924 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6951449 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |